vTv Therapeutics (NASDAQ:VTVT) Rating Increased to Strong-Buy at Roth Mkm

Roth Mkm upgraded shares of vTv Therapeutics (NASDAQ:VTVT) to a strong-buy rating in a research report report published on Thursday morning,Zacks.com reports.

Other research analysts have also issued reports about the company. BTIG Research assumed coverage on vTv Therapeutics in a report on Wednesday, November 19th. They set a “buy” rating and a $40.00 price target for the company. Wall Street Zen raised shares of vTv Therapeutics to a “sell” rating in a research report on Saturday, December 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of vTv Therapeutics in a research note on Monday, December 29th. TD Cowen assumed coverage on shares of vTv Therapeutics in a research report on Monday, January 5th. They issued a “buy” rating on the stock. Finally, HC Wainwright restated a “buy” rating and set a $47.00 price objective (up previously from $36.00) on shares of vTv Therapeutics in a report on Friday, December 19th. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, vTv Therapeutics currently has an average rating of “Buy” and an average target price of $53.00.

vTv Therapeutics Price Performance

VTVT stock opened at $34.11 on Thursday. The stock has a market capitalization of $134.39 million, a price-to-earnings ratio of -10.27 and a beta of 0.48. The company has a 50-day moving average of $34.03 and a two-hundred day moving average of $24.59. vTv Therapeutics has a 52-week low of $13.96 and a 52-week high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.11).

Hedge Funds Weigh In On vTv Therapeutics

A hedge fund recently raised its stake in vTv Therapeutics stock. Baker BROS. Advisors LP grew its position in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) by 52.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 148,314 shares of the biotechnology company’s stock after buying an additional 51,000 shares during the quarter. Baker BROS. Advisors LP owned approximately 3.77% of vTv Therapeutics worth $3,463,000 as of its most recent filing with the Securities and Exchange Commission. 17.51% of the stock is owned by hedge funds and other institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.